GLD flexes muscle-wasting ambitions, launching Altagenics with an assist from Heligenics

GLD Partners has secured access to Heligenics’ GigaAssay platform to launch Altagenics, a startup with ambitions to develop first-in-class medicines for muscle-wasting conditions. 

2025: Tariffs, Transition, and Why “America First” Is More Than a Slogan

The idea behind tariffs is that short-term pain is worth long-term gain, a notion now being voiced more frequently by commentators.